These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

232 related articles for article (PubMed ID: 33807238)

  • 1. Insights into the Role of the Microbiota and of Short-Chain Fatty Acids in Rubinstein-Taybi Syndrome.
    Di Fede E; Ottaviano E; Grazioli P; Ceccarani C; Galeone A; Parodi C; Colombo EA; Bassanini G; Fazio G; Severgnini M; Milani D; Verduci E; Vaccari T; Massa V; Borghi E; Gervasini C
    Int J Mol Sci; 2021 Mar; 22(7):. PubMed ID: 33807238
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Rubinstein-Taybi Syndrome and Epigenetic Alterations.
    Korzus E
    Adv Exp Med Biol; 2017; 978():39-62. PubMed ID: 28523540
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Histone acetylation deficits in lymphoblastoid cell lines from patients with Rubinstein-Taybi syndrome.
    Lopez-Atalaya JP; Gervasini C; Mottadelli F; Spena S; Piccione M; Scarano G; Selicorni A; Barco A; Larizza L
    J Med Genet; 2012 Jan; 49(1):66-74. PubMed ID: 21984751
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Epigenetic mechanisms of Rubinstein-Taybi syndrome.
    Park E; Kim Y; Ryu H; Kowall NW; Lee J; Ryu H
    Neuromolecular Med; 2014 Mar; 16(1):16-24. PubMed ID: 24381114
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Syndromic features and mild cognitive impairment in mice with genetic reduction on p300 activity: Differential contribution of p300 and CBP to Rubinstein-Taybi syndrome etiology.
    Viosca J; Lopez-Atalaya JP; Olivares R; Eckner R; Barco A
    Neurobiol Dis; 2010 Jan; 37(1):186-94. PubMed ID: 19822209
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Histone Deacetylase Inhibitors Ameliorate Morphological Defects and Hypoexcitability of iPSC-Neurons from Rubinstein-Taybi Patients.
    Alari V; Scalmani P; Ajmone PF; Perego S; Avignone S; Catusi I; Lonati PA; Borghi MO; Finelli P; Terragni B; Mantegazza M; Russo S; Larizza L
    Int J Mol Sci; 2021 May; 22(11):. PubMed ID: 34071322
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mutations in CREBBP and EP300 genes affect DNA repair of oxidative damage in Rubinstein-Taybi syndrome cells.
    Dutto I; Scalera C; Tillhon M; Ticli G; Passaniti G; Cazzalini O; Savio M; Stivala LA; Gervasini C; Larizza L; Prosperi E
    Carcinogenesis; 2020 May; 41(3):257-266. PubMed ID: 31504229
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Chemical and genetic rescue of an ep300 knockdown model for Rubinstein Taybi Syndrome in zebrafish.
    Babu A; Kamaraj M; Basu M; Mukherjee D; Kapoor S; Ranjan S; Swamy MM; Kaypee S; Scaria V; Kundu TK; Sachidanandan C
    Biochim Biophys Acta Mol Basis Dis; 2018 Apr; 1864(4 Pt A):1203-1215. PubMed ID: 29409755
    [TBL] [Abstract][Full Text] [Related]  

  • 9. iPSC-derived neurons of CREBBP- and EP300-mutated Rubinstein-Taybi syndrome patients show morphological alterations and hypoexcitability.
    Alari V; Russo S; Terragni B; Ajmone PF; Sironi A; Catusi I; Calzari L; Concolino D; Marotta R; Milani D; Giardino D; Mantegazza M; Gervasini C; Finelli P; Larizza L
    Stem Cell Res; 2018 Jul; 30():130-140. PubMed ID: 29883886
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CBP-HSF2 structural and functional interplay in Rubinstein-Taybi neurodevelopmental disorder.
    de Thonel A; Ahlskog JK; Daupin K; Dubreuil V; Berthelet J; Chaput C; Pires G; Leonetti C; Abane R; Barris LC; Leray I; Aalto AL; Naceri S; Cordonnier M; Benasolo C; Sanial M; Duchateau A; Vihervaara A; Puustinen MC; Miozzo F; Fergelot P; Lebigot É; Verloes A; Gressens P; Lacombe D; Gobbo J; Garrido C; Westerheide SD; David L; Petitjean M; Taboureau O; Rodrigues-Lima F; Passemard S; Sabéran-Djoneidi D; Nguyen L; Lancaster M; Sistonen L; Mezger V
    Nat Commun; 2022 Nov; 13(1):7002. PubMed ID: 36385105
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Rubinstein-Taybi syndrome.
    Kosaki R
    Nihon Rinsho; 2017 Mar; 75(3):498-503. PubMed ID: 30566799
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ablation of CBP in forebrain principal neurons causes modest memory and transcriptional defects and a dramatic reduction of histone acetylation but does not affect cell viability.
    Valor LM; Pulopulos MM; Jimenez-Minchan M; Olivares R; Lutz B; Barco A
    J Neurosci; 2011 Feb; 31(5):1652-63. PubMed ID: 21289174
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Rubinstein-Taybi syndrome: clinical and molecular overview.
    Roelfsema JH; Peters DJ
    Expert Rev Mol Med; 2007 Aug; 9(23):1-16. PubMed ID: 17942008
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Rubinstein-Taybi 2 associated to novel EP300 mutations: deepening the clinical and genetic spectrum.
    López M; García-Oguiza A; Armstrong J; García-Cobaleda I; García-Miñaur S; Santos-Simarro F; Seidel V; Domínguez-Garrido E
    BMC Med Genet; 2018 Mar; 19(1):36. PubMed ID: 29506490
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Menke-Hennekam syndrome; delineation of domain-specific subtypes with distinct clinical and DNA methylation profiles.
    Haghshenas S; Bout HJ; Schijns JM; Levy MA; Kerkhof J; Bhai P; McConkey H; Jenkins ZA; Williams EM; Halliday BJ; Huisman SA; Lauffer P; de Waard V; Witteveen L; Banka S; Brady AF; Galazzi E; van Gils J; Hurst ACE; Kaiser FJ; Lacombe D; Martinez-Monseny AF; Fergelot P; Monteiro FP; Parenti I; Persani L; Santos-Simarro F; Simpson BN; ; Alders M; Robertson SP; Sadikovic B; Menke LA
    HGG Adv; 2024 Jul; 5(3):100287. PubMed ID: 38553851
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CREB-binding protein, p300, butyrate, and Wnt signaling in colorectal cancer.
    Bordonaro M; Lazarova DL
    World J Gastroenterol; 2015 Jul; 21(27):8238-48. PubMed ID: 26217075
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Screening of a large Rubinstein-Taybi cohort identified many novel variants and emphasizes the importance of the CREBBP histone acetyltransferase domain.
    Cross E; Duncan-Flavell PJ; Howarth RJ; Hobbs JI; Thomas NS; Bunyan DJ
    Am J Med Genet A; 2020 Nov; 182(11):2508-2520. PubMed ID: 32827181
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Epigenetic factors in intellectual disability: the Rubinstein-Taybi syndrome as a paradigm of neurodevelopmental disorder with epigenetic origin.
    Lopez-Atalaya JP; Valor LM; Barco A
    Prog Mol Biol Transl Sci; 2014; 128():139-76. PubMed ID: 25410544
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Short chain fatty acid butyrate uptake reduces expressions of prostanoid EP
    Kurata N; Tokashiki N; Fukushima K; Misao T; Hasuoka N; Kitagawa K; Mashimo M; Regan JW; Murayama T; Fujino H
    Eur J Pharmacol; 2019 Jun; 853():308-315. PubMed ID: 30980797
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Genetic heterogeneity in Rubinstein-Taybi syndrome: mutations in both the CBP and EP300 genes cause disease.
    Roelfsema JH; White SJ; Ariyürek Y; Bartholdi D; Niedrist D; Papadia F; Bacino CA; den Dunnen JT; van Ommen GJ; Breuning MH; Hennekam RC; Peters DJ
    Am J Hum Genet; 2005 Apr; 76(4):572-80. PubMed ID: 15706485
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.